Compare Sterling Biotech with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs GLENMARK PHARMA - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH GLENMARK PHARMA STERLING BIOTECH/
GLENMARK PHARMA
 
P/E (TTM) x -0.4 10.6 - View Chart
P/BV x 0.0 1.5 0.9% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 STERLING BIOTECH   GLENMARK PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
GLENMARK PHARMA
Mar-19
STERLING BIOTECH/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs11712 1.5%   
Low Rs3484 0.7%   
Sales per share (Unadj.) Rs26.8349.6 7.7%  
Earnings per share (Unadj.) Rs-15.032.8 -45.6%  
Cash flow per share (Unadj.) Rs-5.544.3 -12.3%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs54.9198.6 27.6%  
Shares outstanding (eoy) m267.87282.17 94.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.7 15.2%   
Avg P/E ratio x-0.518.2 -2.5%  
P/CF ratio (eoy) x-1.313.5 -9.4%  
Price / Book Value ratio x0.13.0 4.2%  
Dividend payout %06.1 0.0%   
Avg Mkt Cap Rs m1,862168,625 1.1%   
No. of employees `0001.412.0 11.2%   
Total wages/salary Rs m54720,561 2.7%   
Avg. sales/employee Rs Th5,303.38,196.0 64.7%   
Avg. wages/employee Rs Th403.81,708.1 23.6%   
Avg. net profit/employee Rs Th-2,959.0768.5 -385.1%   
INCOME DATA
Net Sales Rs m7,18198,655 7.3%  
Other income Rs m432,081 2.0%   
Total revenues Rs m7,223100,736 7.2%   
Gross profit Rs m94715,858 6.0%  
Depreciation Rs m2,5433,259 78.0%   
Interest Rs m4,3773,346 130.8%   
Profit before tax Rs m-5,93111,335 -52.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m-1,9243,756 -51.2%   
Profit after tax Rs m-4,0079,250 -43.3%  
Gross profit margin %13.216.1 82.0%  
Effective tax rate %32.433.1 97.9%   
Net profit margin %-55.89.4 -595.1%  
BALANCE SHEET DATA
Current assets Rs m14,33566,968 21.4%   
Current liabilities Rs m49,80940,211 123.9%   
Net working cap to sales %-494.027.1 -1,821.5%  
Current ratio x0.31.7 17.3%  
Inventory Days Days40383 484.1%  
Debtors Days Days17181 210.2%  
Net fixed assets Rs m55,43233,322 166.4%   
Share capital Rs m268282 94.9%   
"Free" reserves Rs m13,93555,770 25.0%   
Net worth Rs m14,70156,052 26.2%   
Long term debt Rs m9,47835,738 26.5%   
Total assets Rs m73,988132,888 55.7%  
Interest coverage x-0.44.4 -8.1%   
Debt to equity ratio x0.60.6 101.1%  
Sales to assets ratio x0.10.7 13.1%   
Return on assets %0.59.5 5.3%  
Return on equity %-27.316.5 -165.1%  
Return on capital %-6.417.8 -36.1%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86062,998 3.0%   
Fx outflow Rs m2522,859 0.1%   
Net fx Rs m1,83540,140 4.6%   
CASH FLOW
From Operations Rs m1,71913,242 13.0%  
From Investments Rs m-3,148-6,990 45.0%  
From Financial Activity Rs m1,426-7,387 -19.3%  
Net Cashflow Rs m-3-2,971 0.1%  

Share Holding

Indian Promoters % 33.9 48.3 70.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 6.9 -  
FIIs % 9.9 34.4 28.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 10.5 374.3%  
Shareholders   21,482 56,727 37.9%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON   

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - UNICHEM LAB COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS